Clinical Trial Update: Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial of Xisomab 3G3 for preventing catheter-associated thrombosis in cancer patients undergoing chemotherapy was terminated; results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Malignant Solid Neoplasm
• Plasma Cell Myeloma

Drugs mentioned

• Xisomab 3G3 (Xisomab 3G3)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Lymphoma, Malignant Solid Neoplasm | Phase 2 | Status: TERMINATED | Results posted: 2024-01-02